Down-regulation of leucocyte immunoglobulin-like receptor expression in the synovium of rheumatoid arthritis patients after treatment with disease-modifying anti-rheumatic drugs

Rheumatology

Volumn 46, Issue 5, 2007, Pages 742-751

  Huynh, O A ^a   Hampartzoumian, T ^a   Arm, J P ^b   Hunt, J ^a   Borges, L ^c   Ahern, M ^d   Smith, M ^d   Geczy, C L ^a   McNeil, H P ^a,e   Tedla, N ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AMGEN INC   (United States)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

Author keywords

Disease modifying anti rheumatic drugs; Leucocyte immunoglobulin like receptors; Rheumatoid arthritis

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD COMPLEX; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN A2 RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN B2 RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN B3 RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; PREDNISOLONE; RECEPTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; FC RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 3, HUMAN; LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 3, HUMAN; LILRA2 PROTEIN, HUMAN; LILRB2 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; JOINT BIOPSY; MACROPHAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; CELL CULTURE; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; MIDDLE AGED; SYNOVIUM;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, FC; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE;

EID: 34347254684     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel405     Document Type: Article

References (49)

1. Brahee DD, Pierre-Jerome C, Kettner NW. Clinical and radiological manifestations of the rheumatoid wrist. A comprehensive review. J Manipulative Physiol Ther 2003;26:323-9.
2. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619-33.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Korpela M, Laasonen L, Hannonen P et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
5. Case JP. Old and new drugs used in rheumatoid arthritis: A historical perspective. Part 2: The newer drugs and drug strategies. Am J Ther 2001;8:163-79.
6. Long EO, Lanier LL, Colonna. M, Cosman D. Now Nomenclature for the leukocyte immunoglobulin-like receptors on 19q13. http://www.gene.ucl.ac.uk(nomenclature/genefamily/lilr.html 2001.
7. Colonna M, Navarro F, Bellon T et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997;186:1809-18.
8. Tedla N, Bandeira-Melo C, Tassinari P et al. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci U S A 2003;100:1174-9.
9. Sloane DE, Tedla N, Awoniyi M et al. Leukocyte immunoglobulin-like receptors: Novel innate receptors for human basophil activation and inhibition. Blood 2004;104:2832-9.
10. Colonna M, Samaridis J, Cella M et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998;160:3096-100.
11. Fanger NA, Cosman D, Peterson L et al. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol 1998;28:3423-34.
12. Tedla N, Gibson K, McNeil HP et al. The co-expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium. Am J Pathol 2002;160:425-31.
13. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. Pinals RS, Baum J, Bland J et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Bull Rheum Dis 1982;32:7-10.
16. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
17. Tedla N, Palladinetti P, Kelly M et al. Chemokines and T lymphocyte recruitment to lymph nodes in HIV infection. Am J Pathol 1996;148:1367-73.
18. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
19. Ferret PJ, Soum E, Negre O, Wollman EE, Fradelizi D. Protective effect of thioredoxin upon NO-mediated cell injury in THP1 monocytic human calls. Biochem J 2000;346:759-65.
20. Lavagno L, Bordin G, Colangelo D, Viano I, Brunelleschi S. Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A. Neuropeptides 2001;35:92-9.
21. Seitz M, Dayer JM. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment. Rheumatology 2000;39:637-45.
22. Tsiavou A, Degiannis D, Hatziagelaki E, Koniavitou K, Raptis S. Flow cytometric detection of intracellular IL-12 release: in vitro effect of widely used immunosuppressants. Int Immunopharmacol 2002;2:1713-20.
23. van der Goes A, Hoekstra K, van den Berg TK, Dijkstra CD. Dexamethasone promotes phagocylosis and bacterial killing by human monocytes/ macrophages in vitro. J Leukoc Biol 2000;67:801-7.
24. Pascalis L, Aresu G, Pia G. Long-term efficacy and toxicity of cyclosporin A + fluocortolone + methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 1999;17:679-88.
25. Gerards AH, Landewe RB, Prins AP et al. Cyclosporin A monotherapy versus cyclosporin A and mathotrexate combination therapy in patients with early rheumatoid arthritis: A double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62:291-6.
26. Kim JT, Gleich GJ, Kita H. Roles of CD9 molecules in survival and activation of human eosinophils. J Immunol 1997;159:926-33.
27. Smith MD, Kraan MC, Slavotinek J et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology 2001;40:367-74.
28. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994;53;315-22.
29. Dolhain RJ, Tak PP, Dijkmans BA et al. Mothatroxate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998;37:502-8.
30. Walters MT, Smith JL, Moore K, Evans PR, Cawley MI. An investigation of the action of disease modifying antirheumatic drugs on the rheumatoid synovial membrane: Reduction in T lymphocyte subpopulations and HLA-DP and DQ antigen expression after gold or penicillamine therapy. Ann Rheum Dis 1987;46:7-16.
31. Rooney M, Whelan A, Feighery C, Bresnihan B. Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis. Arthritis Rheum 1989;32:361-9.
32. Tak PP, Taylor PC, Breadveld FC et al. Decrease in cellularity, and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39: 1077-81.
33. Soden M, Rooney M, Whelan A, Feighery C, Bresnihan B. Immunohistological analysis of the synovial membrane: Search for predictors of the clinical course in rheumatoid arthritis. Ann Rheum Dis 1991;50:673-6.
34. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: Targeting cytokines. Ann N Y Acad Sol 2005;1051:716-29.
35. Newton R. Molecular mechanisms of glucocorticoid action: What is important? Thorax 2000;55:603-13.
36. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-Induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: Preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 1999;127:1003-11.
37. Fauci AS, Dale DC, Below JE. Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
38. Korhonen R, Lahti A, Hamalainen M, Kankaanranta H, Moilanen E, Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages. Mol Pharmacol 2002,62:698-704.
39. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 1997;159:5192-6.
40. Steer JH, Vuong Q, Joyce DA. Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: Relationship to systemic monocytopaenia and cortisol suppression. Br J Clin Pharmacol 1997;43:383-9.
41. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
42. Di Girolamo N, Indoh I, Jackson N et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: Role in cell migration. J Immunol 2006;177:2638-50.
43. Kim-Schulze S, Saki T, Vlad G et al. Regulation of ILT3 gone expression by processing of precursor transcripts in human andothelial cells. Am J Transplant 2006;6:76-82.
44. Manavalan JS, Kim-Schulze S, Scotto L et al. Alloantigen specific CD8+CD28-FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004;16:1055-68.
45. Yen JH, Moore BE, Nakajima T et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001;193:1159-67.
46. Mornot T, Koch S, Hunzelmann N et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004;50:1561-5.
47. Martin MP, Nelson G, Lee JH et al. Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002;169:2818-22.
48. Lanier LL. NK cell recognition. Annu Rev Immunol 2005:23:225-74.
49. Chan AT, Kollnberger SD, Wedderbum LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005;52:3588-95.